The global GLP-1 receptor agonist market size stood at around USD 11.3 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Formulation advancements of GLP-1 receptor agonist coupled with the presence of robust product pipeline is expected to drive the market over the forecast period. As per the International Diabetes Federation in 2019, around 463 million people aged 20 – 79 years were estimated to be diabetic worldwide. Furthermore, overweight and obese people are exposed to the risks of developing diabetes and cardiovascular diseases. According to WHO, in 2016, over 1.9 billion adults were found to be overweight which may result in increased usage of GLP-1 receptor agonist.
Formulation advancements of GLP – 1 receptor agonist, presence of strong product pipeline, favourable reimbursement policies and increase in the prevalence rate of lifestyle diseases are the major market drivers of GLP-1 global market. Innovative products are being developed which are expected to accelerate the growth of the market for GLP-1 receptor agonist. Pharmaceutical companies are making innovations in terms of formulations, improved bioavailability, combination therapies, and route of administration. In addition, companies are engaged in developing novel GLP-1 products. For instance, Sanofi in collaboration with HanmiPharm.Co. Ltd are developing efpeglenatide, a GLP-1 receptor agonist for type 2 diabetes and obesity. It is currently undergoing phase-3study.